508
www.onkologiecs.cz3408040010765133201214262311348396415464514532576617652669709748
7956558020012657114
/39938040010732
Onkologie.40708040010760109147194214262312331375389
2025;19(2):76-794479804001074487128172185223261285327350364406446476515557
/50818040010732
ONKOLOGIE51598040010760120166226269329388409452
HLAVNÍ4945200012671127198263336370
TÉMA5337200012657114204274
Role349936001063374106138
imunoterapie365236001061670110151192223255291332367384416
v4083360010637
léčbě41353600106296296132165
metastatického431536001065284117154188220257285303337373405447487
uroteliálního481836001063974115146178209227267298339357398439
karcinomu527236001063476111146163204245299340
10.340630085367085
Balar438630083356884116137
AV,588630083417583
Galsky685630083437691117147181
MD,87963008355101112
Rosenberg10046300833573100135173212248269307
JE,1324630083255871
et14086300833456
al.1478630083314760
Atezolizumab1551630083416296125163178193222261319351390
as19546300833259
first-line34073008317345582105125141156194229
treatment584730083224377109131189224262283
in8827300831553
cisplatin-ineligible950730083314672111127159181196234256272310345361376415430469485520
patients1484730083397294109144182203231
with1730730083506688127
locally1871730083155386119340830083153062
advanced4198300833271103136174207240280
and7168300833270109
metastatic8428300835893115148174197230252267299
urothelial1159830083375895117155190206221253268
carcinoma:1444830083326486117132170208266299311
a177283008332
single-1821830083264179118133168191
-arm,340930083215273130142
multicentre,4949300835793108130145176209246267287321332
phase8389300833876107133167
2101893008333
trial.106393008322435889104116
Lancet.11919300833164101132165187199
2017;389(10064):67-76.1403930083336697126135169203237255286317352387422439451485517535566597610
11.3401030085366678
Galsky4311030083447691117147181
MD,625103008354100110
Hahn74810300834477114152
NM,91310300834599113
Rosenberg103910300833573100134172211247268306
J,135810300832436
et140610300833456
al.14751030083324760
Treatment15481030083325083115137195230267289
of185010300833756
patients1919103008338713401130083223772110131159
with5151130083506688126
metastatic65711300835893115148174197230252267299
urothelial9721130083375896117156191206221253269
cancer125611300833164102135168189
„unfit“14611130083215896114131153176
for16531130083195678
Cisplatin-17471130083395581120136168190205243265
-based3401230083216194120155195
chemotherapy.55012300833169104162201223261296317350389420430
J996123008324
Clin10351230083405570108
Oncol.115912300834785117154170183
2011;29(17):2432-2438.135712300833569100128136171205225256286305317352384417449470501532565599613
12.3401330085377086
Grivas4481330083456784117152179
P,64913300833641
Grande71113300834567102141181217
E,95013300833347
Davis101913300834680112129156
ID,11961330083166374
et129213300833558
al.13711330083334963
Avelumab145513300834274109126164224258298
first-line1775133008317345685109129146162201237
maintenance34014300835790105143164198236268306339372
treatment7281430083224377109131189224262284
for10281430083185677
advanced112114300833271104137175207241280
urothelial14171430083385996118156191207222254269
carcinoma:17021430083316485116131169208266298310
review3401530083215587103138189
of54915300833757
evidence6261530083346682121156194226260
to90615300832259
guide9851530083397691130165
clinical1171153008331466199114146179194
practice.13861530083396093125150165197231243
ESMO164915300833367121169
Open.183815300834787123161174
2023;8(6):102050.34016300833468101136147183202235253265295326359393427461474
13.3401730085377187
Powles45117300833675128145181210
TB,6851730083337286
Perez7951730083367193129160
Valderrama9791730083377086127164186209244304338
B,134117300833650
Gupta141517300834585126149184
S,162317300833347
et169417300833559
al.17771730083334963
LBA6186417300833270113149
EV-302/KEYNOTE-A39:3401830083347395128164199226264299338385435469504527569606641655
Open-label,101718300834889126166189206240281318334347
randomized13861830083215595135175235251282317358
phase176618300834080113141177
III19651830083153147
study3401930083265088127160
of52019300833857
enfortumab5981930083347392130151176215273306345
vedotin96419300833266106145167182220
in120519300831553
combination127919300833168127167182221253275291329368
with16681930083506689127
pembrolizumab181619300833975133173340203008321587490119158216248288
(EV+P)6492030083185290130165183
vs85320300833259
chemotherapy93320300833170105163202224262298319353392424
(Chemo)13772030083195897132190229247
in164420300831553
previously17182030083396195128143182220247262294
untreated3402130083377597118152184206240279
locally6332130083145285118133148180
advanced82721300833170103136174206240279
metastatic112021300835792115147174197230252267299
urothelial14322130083375996118156191206221253269
carcinoma17142130083316485116132169208266298
(la/mUC).340223008319346793149193234254265
Annals62122300834179117149164190
of82722300833756
Oncology.89922300834785117154170208248280290
2023;34:S1340.120422300833469101136148183218230264294324360396408
14.3402330085356781
Powles43223300833570120134168193
T,63623300833240
Valderrama6872330083356579117150170191223279310
BP,10082330083356973
Gupta109223300834379117138169
S,127223300833244
et132723300833455
al.13932330083314557
Enfortumab14612330083326886122143166203259290328
Vedotin180023300833566104141162176212
and34024300833269107
Pembrolizumab46524300833568125164185221236251279317374405444
in92724300831451
Untreated99624300834481102123156187208241280
Advanced129424300834178110143180211244283
Urothelial159524300834464100122159193208223254268
Cancer.188124300834072110340253008331648594
New44825300834579130
England59225300833269108122154191229
Journal83525300832562100120158190204
of105325300833756
Medicine.112325300835489128142173188225259271
2024;390(10):875-888.14082530083346799131142176208244262293324342353387419451473508543577590
15.3402630085366883
Grande4432630083446598136175210
E,67326300833346
Birtle739263008335507196112146
AJ,9052630083416880
Kamat100526300833569127159181
AM.120626300834096110
Re:13362630083357083
Thomas143926300833271110168200227
Powles,168626300833572123138173200213
Begoña19192630083357134027300833979119153
Pérez-Valderrama,5152730083367194129160183220253269310346368391426486520534
Shilpa10712730083337389105145180
Gupta,127327300834585125149183197
et149227300833558
al.15722730083334963
Enfortumab16572730083347393133155181221281315355
Vedotin21406300833669109147170185223
and23846300833270110
Pembrolizumab25146300833670128168189227243258288326385417457
in29926300831453
Untreated30656300834483104126160193215249289
Advanced33746300834180113146185217251291
Urothelial368663008344651032140730083226299115131165181
Cancer.23447300834175115148184206217
N258473008346
Engl26527300833473114130
J280573008324
Med28527300835693134
2024;390:875-888.30087300833671106139152188223260274311345379403440477514528
Eur3559730083347294
Urol.36757300834668106123137
2024;86(6):e152-e153.21408300833468101133145180215234268286298332362392425445482512542575587
16.2140930085366985
van22409300833265103
der2357930083387394
Heijden2466930083447994110149183222
MS,27029300835588100
Sonpavde28179300833371109148181213251286
G,31189300834457
Powles31909300833572123139173200
T,34059300833241
et34619300833456
al.3532930083324760
Nivolumab3607930083446092130146183214010300835789128
plus22801030083395592118
Gemcitabine-Cisplatin241010300834479136168183205238276292329364387429444470508524556577592630
in305310300831452
Advanced311710300834179111144182213247286
Urothelial341510300834465101123161196211226257272
Carcinoma.3700103008340729321401130083314684122181213226
N2382113008344
Engl244211300833270109124
J2582113008324
Med.262111300835590129142
2023;389(19):1778-1789.277911300833468101136147182217251270302332350362392421455489512542572605639650
17.21401230085356675
Sharma222712300833269100121178209
P,244812300833539
Retz24991230083356991121
M,263212300835366
Siefker-Radtke2710123008332468098130164184203239271309331361394
A,311612300834054
et318212300833355
al.32491230083314658
Nivolumab33191230083445991127142179236267305
in363612300831552
metastatic37001230083569021401330083225481104137159174206
urothelial23641330083385996118156191207222254269
carcinoma26511330083326486117132170208266299
after29681330083325176109131
platinum31171330083395587109124162199257
therapy33931330083215994116149188219
(CheckMate36301330083195896131164214014300833086119141174
275):233514300833467100118130
a2485143008332
multicentre,253814300835795110132148180213252273295329341
single-arm,28991430083264179118133168191224245303316
phase323514300833978110137172
23427143008334
trial.3482143008321435890106119
Lancet362114300833165103135169191
Oncol.214015300834786118155171184
2017;18(3):312-322.233915300833468100129139169200219253270282317348378398431463498511
18.21401630085366984
Powles223716300833571121137171198
T,244716300833241
Durán250116300834582103136173
I,268716300831427
van272616300833264102
der28401630083387293
Heijden29461630083437893108146180218
MS,31761630083548799
et328816300833455
al.33561630083314759
Atezolizumab34281630083406194123160176190219257314346385
versus21401730083316585112148174
chemotherapy232617300833168103160197218256290311343381412
in275017300831552
patients28141730083387092106140178199226
with30521730083506587124
platinum-treated31881730083395486107121159195252274296317350381403436474
locally3675173008314528411621401830083153061
advanced221318300833270103135173204238277
or250218300833758
metastatic257318300835791113146172195227249264295
urothelial28811830083365794116153188203218249264
carcinoma31581830083316384115130167205263294
(IMvigor211):34651830083183387119135173211232263294321336347
a2140193008332
multicentre,219319300835795111133149181215253275297331343
open-label,255719300833777113151174190223262298314326
phase290419300833978110137172
33097193008334
randomised31521930083215492131170229244270305345
controlled351819300833168107129151188204219254294
trial.2140203008322435991106119
Lancet.227420300833265103135169191205
2018;391(10122):748-757.249420300833468100131143178211243259290322353383418436448481512548570602634668674
19.21402130085366982
Rosenberg223621300833574100135173213248269308
JE,25572130083245871
Hoffman-Censits264221300834482102121179212250272315349387413428451478
J,313421300832436
Powles318421300833572123139173200
T,339821300833341
et345321300833456
al.35232130083324760
Atezolizumab35972130083416296125163179193214022300832866123155194
in234622300831552
patients24102230083397193108142179201228
with26502230083516688126
locally27882230083155285117132147178
advanced297922300833170102134172204237276
and326722300833269108
metastatic338722300835792114146172195227249264295
urothelial3695223008337579421402330083225994110125156171
carcinoma23242330083316485116131168206264297
who263323300835189127
have277323300833769101135
progressed29202330083396097137158191218245279319
following3251233008319567287125175191228267
treatment35312330083224377108130187222260281
with21402430083506587125
platinum-based22772430083395486107122159196253276315347373408447
chemotherapy:273624300833169103160198219257292312345383414427
a3176243008331
single-arm,32202430083264077116131165188219240298310
multicentre,3543243008357941091301451772102482140253008322437789
phase224425300833978110136171
22431253008334
trial.2480253008322435991106119
Lancet.261525300833164102135168191204
2016;387(10031):1909-1920.283425300833468100131144179213246262294326362395426440452482512548583607637668701735747
20.21402630085367288
Alhalabi22482630083415795127143175215230
O,249926300834759
Campbell257826300834073131171211247262278
M,287626300835568
Shah296526300833371103142
A,312726300834156
et320326300833457
al.32812630083314760
Emerging336226300833290126147185201239278
treatments36612630083214377109131214027300835996136159188
in235427300831554
advanced243427300833374108143183216252293
urothelial275327300833861100123163200217233266283
cancer.306227300833266106140175198210
Curr329727300834179102125
Opin344827300834890106146
Oncol.362027300834889122161178192
2020;32(3):232-239.39406300833468101135148183216233267284296331366398419449484517528
21.3940730085366981
Kawashima40347300833568118151177215230287319
A,43667300834155
Ishizuya443373008315417893122160192225
Y,46707300833543
Yamamoto47267300833564122154211250271308
Y,50477300833543
et51037300833355
al.5171730083324760
Recent52437300833670103136174195
developments545173008338731051393940830083155392150185223244272
and42258300833169108
future4346830083185779117138172
directions4531830083385374107140164179217255281
of48258300833756
first-line489483008317345582105125141156193228
systemic5135830083265885108142199214246
therapy5394830083226094116148187218
combined39409300833168126165181218253293
with4246930083506688126
immunotherapy43859300831572130167205243265303338359392431462
for4860930083195678
advanced49519300833170103136174206239279
or52439300833758
metastatic53149300835892115147174197230251267298
urothelial39401030083375896117156191206221253269
carcinoma:42271030083316485116131169207266298310
a4556103008331
historical46061030083375278102139160176208241256
perspective48801030083397596123162198230254270302336
on523510300833775
treatment53291030083214377109131189224262283
evolution.394011300833466104120157180195233271285
Int42401130083155374
J4330113008324
Clin43691130083405570108
Oncol.449211300834786118155171184
2024;29(8):1096-1104.469111300833468101133145180214233267285297327358393429452483511542578591
22.39401230085367287
Ascione404012300834168100115152190225
CM,427712300834095108
Napolitano439712300834577115154170184206239276314
F,472412300833238
Esposito47741230083326098137163177200236
D,502312300834555
et509112300833455
al.51591230083324759
Role52311230083357389123
of536712300833655
FGFR3543512300833276108143178
in394013300831553
bladder40081330083385486126165200221
cancer:424413300833164102134168189203
Treatment44621330083335084116138196231269290
landscape47681330083144785124150182215254290
and507313300833270109
future51971330083185780118139173
challenges.538513300833169102117132167205394014300833873100113
Cancer406914300834072111143176198
Treat42821430083325084116137
Rev.443514300833570102112
2023;115:102530.456314300833468101135147177205235246275307340375408442455
23.39401530085377590
Albarrán40521530083425898133155177211251
V,432415300833746
Rosero439215300833675103139161200
DI,46131530083476377
Chamorro471115300834180114173213235258296
J,502915300832537
et508815300833558
al.51671530083334963
Her-2525115300834582104124156
Targeted5429153008333628412416039401630083225695
Therapy405616300833372107128162201232
in430916300831553
Advanced438216300834180113146184216250290
Urothelial469216300834465103125163198214229261277
Cancer:498916300834073111144177199213
From52221630083335390148
Monoclonal53911630083559313217020339401730083155494127143
Antibodies410417300834281103119159199240256291319
to444417300832260
Antibody-Drug452517300834281104119160199240273296344366406446
Conjugates.499217300834178118134172212245268303330344
Int53581730083155476
J5455173008325
Mol550117300835695111
Sci.3940183008332658093
2022;23(20).404818300833468101136148183218236270304323334
24.39401930085367186
Grivas40421930083446581113146173
P,423119300833539
Pouessel428619300833572110145172198233249
D,455119300834556
Park46221930083366789119
CH,47571930083408497
et487019300833356
al.49411930083324861
Sacituzumab50171930083336698113135173203241299331370
Govitecan540319300834482114130153186394020300833164102
in405920300831553
Combination412920300834077135174190228260282297335374
With45202030083577396134
Pembrolizumab467120300833569127166187225240255285323381413452
for51402030083195678
Patients52352030083356789104139177198226
With54782030083587496134
Metastatic394021300835488110142169191223245260291
Urothelial424321300834464101122160194210224256271
Cancer452621300833972109141174195
That473321300833271103124
Progressed48692130083355592131152185212238272311
After51922130083415984117138
Platinum-53422130083354981102117155192249270
-Based39402230083215891117152192
Chemotherapy:414522300833977112170208230268303324357396427441
TROPHY-U-01459922300833269117153197233251296319356388
Cohort500022300834077115153175199
3.521222300833447
J5272223008324
Clin53092230083405570108
Oncol.543022300834685117154170183
2024;42(12):1415-1425.394023300833468101133145180212229261291309321351382412442464495526559594605
25.39402430085367287
Hoffman-Censits404424300834482102121180212250273316349387414429451479
J,454024300832436
Grivas45932430083446581113146173
P,478324300833539
Powles483924300833572123139174201
T,505724300833241
et511524300833456
al.51882430083324760
The526524300833372107
JAVELIN53892430083246497132163178224
Bladder39402530083355183122161196217
Medley417025300835489129144179210
trial:4393253008322435991106118
avelumab-based45242530083326398113151208241280303343376402437477
combinations501425300833168126165180218250272287325364390
as541725300833258
first-5488253008317345582105124
-line3940263008321375290125
maintenance407826300835790105143164198236268306339372
in446326300831553
advanced452926300833271103136174206240280
urothelial48222630083375895117155190206221253268
carcinoma.51032630083326486117132170208266299312
Future54282630083326991129150184
Oncol.394027300834786118155171184
2024;20(4):179-190.413927300833468101133145180214233266284296325355388412443473508521
VÁŠ366459000345191377545
PARTNER42765900034517435954371392610931276
V308962200345191
ONKOUROLOGII33466220034521542961983010411224144416041813202421152207
Astellas34080100975285113155175196236270
Pharma62880100974592133161232273
s.r.o.,919801009734507891138154171
Rohanské110880100974693140181228262302344
nábřeží147080100974788137165206243263
678/29,175180100974387130160203247264
186203380100974488131
00218280100974487
Praha228880100974571112159200
82506801009743
–2568801009742
Karlín,262880100974688116137156204221
www.astellas.com/cz2867801009763126190204245279307349369389430464481519565636665703739
10/202434081100974487116160204247291
|667811009720
MAT-CZ-NON-2024-00011723811009769120155177228275298354413469495539582626669695739783826870913